Q1 Earnings Forecast for Rezolute Issued By HC Wainwright

Rezolute, Inc. (NASDAQ:RZLT) – HC Wainwright issued their Q1 2027 earnings estimates for shares of Rezolute in a report issued on Friday, February 13th. HC Wainwright analyst D. Tsao anticipates that the company will earn ($0.08) per share for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Rezolute’s Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.11) EPS and FY2030 earnings at $0.35 EPS.

Rezolute (NASDAQ:RZLT) last announced its earnings results on Thursday, February 12th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.06).

A number of other research analysts have also commented on the company. Cantor Fitzgerald lowered Rezolute from an “overweight” rating to a “neutral” rating in a research report on Thursday, December 11th. Jefferies Financial Group reiterated a “buy” rating and issued a $20.00 price objective on shares of Rezolute in a research report on Friday, December 5th. Guggenheim reduced their target price on shares of Rezolute from $15.00 to $6.00 and set a “buy” rating on the stock in a research note on Friday, December 12th. BTIG Research reiterated a “buy” rating and set a $5.00 price target on shares of Rezolute in a research report on Thursday, January 8th. Finally, Citizens Jmp downgraded shares of Rezolute from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 11th. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.67.

Rezolute Price Performance

Shares of Rezolute stock opened at $3.84 on Monday. The firm has a 50 day simple moving average of $3.13 and a 200 day simple moving average of $6.53. Rezolute has a fifty-two week low of $1.07 and a fifty-two week high of $11.46. The firm has a market cap of $367.49 million, a P/E ratio of -4.13 and a beta of 0.46.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC increased its holdings in shares of Rezolute by 12.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 2,351,144 shares of the company’s stock worth $5,549,000 after acquiring an additional 251,144 shares in the last quarter. Rafferty Asset Management LLC increased its stake in Rezolute by 163.6% during the 4th quarter. Rafferty Asset Management LLC now owns 139,394 shares of the company’s stock worth $329,000 after purchasing an additional 86,507 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Rezolute by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 665,158 shares of the company’s stock worth $1,570,000 after buying an additional 13,019 shares during the period. State Street Corp raised its holdings in Rezolute by 90.4% during the 4th quarter. State Street Corp now owns 3,981,708 shares of the company’s stock worth $9,397,000 after buying an additional 1,890,232 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new position in Rezolute in the fourth quarter valued at approximately $106,000. 82.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CFO Daron Evans bought 40,000 shares of the stock in a transaction on Monday, December 15th. The stock was purchased at an average price of $1.77 per share, with a total value of $70,800.00. Following the completion of the purchase, the chief financial officer owned 415,900 shares of the company’s stock, valued at approximately $736,143. This trade represents a 10.64% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Nevan C. Elam bought 32,000 shares of the business’s stock in a transaction on Monday, December 15th. The stock was purchased at an average price of $1.59 per share, for a total transaction of $50,880.00. Following the completion of the acquisition, the chief executive officer owned 641,119 shares of the company’s stock, valued at approximately $1,019,379.21. This trade represents a 5.25% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 89,100 shares of company stock worth $150,232 over the last quarter. 14.78% of the stock is currently owned by corporate insiders.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.